Earnings next few days....will again show very little cash in hand.
 Chemistry meeting May 17th is NOT going to have any trial data...think everyone knows that.
They need partnership pronto. I don't think any wk12 data will also help, as without partnership how can they even go into Phase 2/3 ?
easily see stock over 200 by end of year. I assume Minecraft will go live sometime in the summer
it is NOT a scientific conference,....it is a chemistry meeting. Look it up. THERE WILL BE NO DATA COMING HERE.
no one is even giving them funds to start ph 2/3 for ALZ !! Forget about Rett.
deeply oversold...average target AFTER Friday warning is about $27-30
walk into a bar...they have a drink...when leaving the bartender asks - 'who is going to pay the bill ?' They all look at each other and say - 'hmm..we don't remember'.
CEO needs to buy shares, so do directors.
CEO needs to start looking at strategic - look for suitors, mergers. At 0.5 book value, this is too cheap and a robust pipeline later this year. He already said board is investor friendly. More generic drug companies needs to merge.
a LOT is priced in already. Go read their earnings transcript....150 products waiting FDA approval, Lots of exciting products coming later in 2016. A 20% drop in earnings does not equate to 50% drop in stock price. All metrics are VERY cheap. P/B, P/S, P/E.
price to book under 0.5, book value is over $26. Someone will scoop them up quick.
this is even lower than LNKD earnings, even after their big selloff last qtr. Don't know why people say FB is overvalued...for its growth it is not expensive at all.
they made 3.12 in Q1....so I assume this year it will be over 13. Current P/E is about 12. Next year will be even lower P/E. Company growing revenue AND earnings both at 100%.
they expect much more efficiencies that will start showing this quarter. Under $30 is a great stock to own.
really ? so he told you this after lunch yesterday ?
The day they announce plan to launch ovature, buy the stock....all rest is not going to set stock moving. Replacing hormone treatment is the big story with this stock. Even CEO says buy the company for ovature, not for rest. I assume all the insider buying at 7s, 9s, etc...are all getting ready for ovature...but that is still 1 year out minimum.
Even Japan for augment is 1 year out.
data means nothing without phase2/3 placebo completed...and that WILL take $$ which company does not have. They are also starting Phase 2 Rett, for which they don't have the $$.
These patient news from Aust, Mr. McFarlane is not going to help...you can see the results, stock is back under $5.
so data, patient news, McFarlane blabbering will not help. ONLY thing will move stock is funding via partnership, which they seem to not be able to get.
$8 billion in dept and market cap under $3 billion, with price erosion is not a good combination.
To think, Allergan just did a $10 billion buyback..they could have easily bought some cheap company. ALL pharma companies are really cheap now. But they did not do it.
Pharmas are doing buyback to boost shares, but not acquisitions. Not a good sign.